Nearly half of all Hepatitis B drug sales will happen in China

China’s hepatitis B market will rise from just under £666.6m ($923m) in 2014 to over £1bn ($1.4bn) by 2024, representing a compound annual growth rate (CAGR) of 4.4%, according to GlobalData

The report [1], which Global Data said covers the eight major markets (8MM) of the US, France, Germany, Italy, Spain, the UK, Japan and China, states that China will continue to dominate the hepatitis B treatment space, as its market share rises from 38.8% in 2014 to 47.2%, nearly half of the market, by 2024.

Daian Cheng, GlobalData’s analyst covering infectious disease, said the hepatitis B market trend will be largely down to natural population growth and China’s huge and increasing drug-treated population, which currently makes up 80% of treated cases across the 8MM.

Cheng said: “China’s proportion of treated cases is much higher than its market share because hepatitis B therapeutics cost much less compared with other regions. Indeed, it is the sheer increase in the number of drug-treated patients that will drive market growth.

“The projected increase of patients alone, nearly 300,000 between 2014 and 2024, is much more than the total number of treated patients in the US, which is around 100,000. Thus, the increase in therapeutic sales will be considerable and China will hang on to its market dominance, even with lower drug prices.”

[1] PharmaPoint: Hepatitis B Virus (HBV) Therapeutics – Global Drug Forecast and Market Analysis to 2024